

Datasheet: HCA221

Description:	HUMAN ANTI CETUXIMAB
Specificity:	CETUXIMAB
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD19830_hIgG1
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody (lambda light chain) selected from the HuCAL? phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein Concentrations	IgG concentration 0.5 mg/ml
Immunogen	Cetuximab.

Specificity **Human anti Cetuximab, clone AbD19830_hIgG1**, is an anti-idiotypic antibody that binds specifically to cetuximab and inhibits the binding of the drug to its target. Human anti Cetuximab, clone AbD19830_hIgG1 can be used to measure the levels of cetuximab and biosimilar products using bioanalytical assays.

In the HRP-conjugated format clone AbD19830_hlgG1 is ideal for use as detection antibody in pharmacokinetic (PK) assays. It is a fully human antibody and therefore may also be used as a calibrator in immune response assays to measure the anti-drug-antibody (ADA) response in patient sera.

Cetuximab (brand name Erbitux®) is a chimeric monoclonal antibody drug (IgG1/kappa) approved for treatment of KRAS wild-type metastatic colorectal cancers and squamous cell carcinoma of the head and neck. This therapeutic antibody, directed against the Epidermal Growth Factor Receptor (EGFR), inhibits tumor cell proliferation by blocking the interaction of Epidermal Growth Factor (EGF) with its receptor.

[View a summary of all anti cetuximab antibodies.](#)

Affinity	The monovalent intrinsic affinity of HCA221 was measured as $K_D=1.7$ nM by real time, label free molecular interaction analysis on immobilized cetuximab.
ELISA	This product may be used in a direct ELISA or as a bridging reagent in ADA assays. Following HRP-conjugation, this product can also be used as a detection reagent in a bridging ELISA for PK assay development together with HCA220 as the capture reagent. Protocol: PK bridging ELISA to measure free drug Protocol: ADA bridging ELISA
Further Reading	1. Gomez, D. <i>et al.</i> (2013) Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier? Int J Surg. 11 (7): 507-13.
Storage	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C. Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Guarantee	12 months from date of despatch
Acknowledgements	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only

Technical Advice Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#)

Related Products

Recommended Useful Reagents

[HUMAN ANTI CETUXIMAB \(HCA220\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M395690:220519'

Printed on 19 May 2022

© 2022 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)